+

WO2005063817A3 - Procédés d'identification d'anticorps fonctionnels - Google Patents

Procédés d'identification d'anticorps fonctionnels Download PDF

Info

Publication number
WO2005063817A3
WO2005063817A3 PCT/US2004/042937 US2004042937W WO2005063817A3 WO 2005063817 A3 WO2005063817 A3 WO 2005063817A3 US 2004042937 W US2004042937 W US 2004042937W WO 2005063817 A3 WO2005063817 A3 WO 2005063817A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
biological function
exhibit
functional antibodies
Prior art date
Application number
PCT/US2004/042937
Other languages
English (en)
Other versions
WO2005063817A2 (fr
Inventor
Wei Yan
Wenyan Shen
Hongxing Zhou
Chen Zhou
David J Cosman
Paul Carter
Francis H Martin
Original Assignee
Amgen Inc
Wei Yan
Wenyan Shen
Hongxing Zhou
Chen Zhou
David J Cosman
Paul Carter
Francis H Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Wei Yan, Wenyan Shen, Hongxing Zhou, Chen Zhou, David J Cosman, Paul Carter, Francis H Martin filed Critical Amgen Inc
Priority to CA002550933A priority Critical patent/CA2550933A1/fr
Priority to AU2004309373A priority patent/AU2004309373A1/en
Priority to EP04815058A priority patent/EP1699825A2/fr
Publication of WO2005063817A2 publication Critical patent/WO2005063817A2/fr
Publication of WO2005063817A3 publication Critical patent/WO2005063817A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés pour cribler des anticorps multimères produits par des cellules mammaires, afin de déterminer ceux qui présentent une fonction biologique. Ces procédés peuvent servir à cribler un grand nombre d'anticorps, lesquels peuvent être dans une surface cellulaire, sécrétés ou intracellulaires. Des anticorps sont criblés pour déterminer ceux qui lient un antigène de façon plus avide ou ceux qui sont en concurrence avec un ligand liant l'antigène pour la liaison. Toute fonction biologique qui peut être testée in vitro peut servir au criblage de ces anticorps. Des acides nucléiques codant lesdits anticorps à fonction biologique peuvent être obtenus de différentes manières.
PCT/US2004/042937 2003-12-22 2004-12-21 Procédés d'identification d'anticorps fonctionnels WO2005063817A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002550933A CA2550933A1 (fr) 2003-12-22 2004-12-21 Procedes d'identification d'anticorps fonctionnels
AU2004309373A AU2004309373A1 (en) 2003-12-22 2004-12-21 Methods for identifying functional antibodies
EP04815058A EP1699825A2 (fr) 2003-12-22 2004-12-21 Procedes d'identification d'anticorps fonctionnels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53171403P 2003-12-22 2003-12-22
US60/531,714 2003-12-22
US60590204P 2004-08-31 2004-08-31
US60/605,902 2004-08-31

Publications (2)

Publication Number Publication Date
WO2005063817A2 WO2005063817A2 (fr) 2005-07-14
WO2005063817A3 true WO2005063817A3 (fr) 2006-03-16

Family

ID=34743002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/042937 WO2005063817A2 (fr) 2003-12-22 2004-12-21 Procédés d'identification d'anticorps fonctionnels

Country Status (5)

Country Link
US (1) US7884054B2 (fr)
EP (1) EP1699825A2 (fr)
AU (1) AU2004309373A1 (fr)
CA (1) CA2550933A1 (fr)
WO (1) WO2005063817A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350178T3 (es) * 2001-10-01 2011-01-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Procedimiento de producción de bibliotecas de proteínas y de selección de proteínas a partir de las mismas.
US7790655B2 (en) * 2005-10-14 2010-09-07 Medimmune, Llc Cell display of antibody libraries
US9109223B2 (en) 2005-12-23 2015-08-18 Viventia Bio, Inc. Methods for generating and screening fusion protein libraries and uses thereof
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PL2069403T3 (pl) 2006-10-02 2015-08-31 Regeneron Pharma Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
WO2008070367A2 (fr) * 2006-11-01 2008-06-12 Facet Biotech Corporation Banques d'affichage d'immunoglobine à base de cellule de mammifère
DK2190987T3 (da) 2007-08-21 2013-02-18 Morphosys Ag Fremgangsmåder til dannelse af disulfidbindinger
US20130338038A1 (en) 2007-12-21 2013-12-19 Pdl Biopharma, Inc. Method of screening complex protein libraries to identify altered properties
US8748151B2 (en) 2008-08-29 2014-06-10 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
WO2010059981A2 (fr) * 2008-11-21 2010-05-27 Dgen Biotech Limited Banque de présentation mammalienne de haute complexité et procédés de criblage
CN103201293B (zh) 2010-09-08 2016-04-27 哈洛齐梅公司 评估和鉴定或发展条件活性治疗蛋白的方法
NZ744109A (en) 2012-08-21 2023-01-27 Regeneron Pharma Methods for treating or preventing asthma by administering an il-4r antagonist
DK2890836T3 (da) * 2012-08-31 2019-09-16 Scripps Research Inst Fremgangsmåder i forbindelse med modulatorer af eukaryotiske celler
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RU2674680C2 (ru) 2013-06-21 2018-12-12 Санофи Байотекнолоджи Способы лечения полипоза носа путем введения антагониста il-4r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR20240128110A (ko) 2014-02-28 2024-08-23 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3218005B1 (fr) 2014-11-12 2023-01-04 Seagen Inc. Composés interagissant avec le glycane et procédés d'utilisation
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
RU2734490C2 (ru) 2014-11-14 2020-10-19 Санофи Байотекнолоджи Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
CA3002097A1 (fr) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Composes interagissant avec le glycane et methodes d'utilisation
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3589319A4 (fr) 2017-03-03 2021-07-14 Seagen Inc. Composés interagissant avec le glycane et méthodes d'utilisation
EP3661537A4 (fr) 2017-08-03 2021-06-09 The Cleveland Clinic Foundation Expression peptidique améliorée et détection d'anticorps de sujet spécifique d'apo-h
WO2019028367A1 (fr) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles active
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
BR112020018691A2 (pt) 2018-03-26 2021-01-05 Regeneron Pharmaceuticals, Inc. Anticorpos anti-pfrh5 e fragmentos de ligação ao antígeno dos mesmos
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
US20220034902A1 (en) * 2018-12-11 2022-02-03 Merck Sharp & Dohme Corp. Method for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of b-cell and hybridoma libraries
US11964016B2 (en) 2019-03-21 2024-04-23 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
KR20220044563A (ko) 2019-08-05 2022-04-08 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
BR112023022878A2 (pt) 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
WO2024152014A1 (fr) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Molécules de liaison à fgfr3 et leurs procédés d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015694A1 (fr) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Modification de genes induite par recombinase dans des cellules de mammifere, compositions et cellules utiles a cet effet
WO1995020401A1 (fr) * 1994-01-31 1995-08-03 Trustees Of Boston University Banques d'anticorps polyclonaux
WO2000055335A1 (fr) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Vecteurs lentiviraux pseudotypes et utilisations de ces vecteurs
WO2003029456A1 (fr) * 2001-10-01 2003-04-10 Dyax Corp. Vecteurs d'affichage eukaryotes multichaine et leurs utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US20050196755A1 (en) 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002102855A2 (fr) 2000-11-17 2002-12-27 University Of Rochester Methodes in vitro de production et d'identification de molecules d'immunoglobulines dans des cellules eucaryotiques
AU2002338446A1 (en) 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
ES2350178T3 (es) * 2001-10-01 2011-01-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Procedimiento de producción de bibliotecas de proteínas y de selección de proteínas a partir de las mismas.
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
DE102009006277B4 (de) 2009-01-27 2015-02-12 Husqvarna Ab Rasenschneidgerät

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015694A1 (fr) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Modification de genes induite par recombinase dans des cellules de mammifere, compositions et cellules utiles a cet effet
WO1995020401A1 (fr) * 1994-01-31 1995-08-03 Trustees Of Boston University Banques d'anticorps polyclonaux
WO2000055335A1 (fr) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Vecteurs lentiviraux pseudotypes et utilisations de ces vecteurs
WO2003029456A1 (fr) * 2001-10-01 2003-04-10 Dyax Corp. Vecteurs d'affichage eukaryotes multichaine et leurs utilisations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEN W ET AL: "A bidirectional phage display vector for the selection and mass transfer of polyclonal antibody libraries", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 222, no. 1-2, January 1999 (1999-01-01), pages 45 - 57, XP004152426, ISSN: 0022-1759 *
FREDERICKS ZOEY L ET AL: "Identification of potent human anti-IL-IRI antagonist antibodies.", PROTEIN ENGINEERING DESIGN & SELECTION, vol. 17, no. 1, January 2004 (2004-01-01), pages 95 - 106, XP002348400, ISSN: 1741-0126 *
HOOGENBOOM HENNIE R: "Selecting and screening recombinant antibody libraries.", NATURE BIOTECHNOLOGY. SEP 2005, vol. 23, no. 9, September 2005 (2005-09-01), pages 1105 - 1116, XP002348401, ISSN: 1087-0156 *
LIANG MIFANG ET AL: "Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 247, no. 1-2, 1 January 2001 (2001-01-01), pages 119 - 130, XP004228405, ISSN: 0022-1759 *
SHARON J ET AL: "RECOMBINANT POLYCLONAL ANTIBODY LIBRARIES", COMBINATORIAL CHEMISTRY AND HIGH THROUGHPUT SCREENING, HILVERSUM, NL, vol. 3, no. 3, June 2000 (2000-06-01), pages 185 - 196, XP001002237, ISSN: 1386-2073 *
STRUBE R W ET AL: "Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-Fc intrabodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 263, no. 1-2, 1 May 2002 (2002-05-01), pages 149 - 167, XP004354392, ISSN: 0022-1759 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Also Published As

Publication number Publication date
AU2004309373A1 (en) 2005-07-14
WO2005063817A2 (fr) 2005-07-14
US7884054B2 (en) 2011-02-08
CA2550933A1 (fr) 2005-07-14
EP1699825A2 (fr) 2006-09-13
US20050282181A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
WO2005063817A3 (fr) Procédés d'identification d'anticorps fonctionnels
AU2002304640A1 (en) Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
WO2004078938A3 (fr) Polypeptides et anticorps derives de cellules de leucemie lymphocytique chronique et utilisations correspondantes
WO2007047578A3 (fr) Affichage cellulaire de libraires d'anticorps
WO2006004663A3 (fr) Augmentation de la production d'anticorps de recombinaison dans des cellules de mamiferes par mutagenese sur le site
WO2006124641A3 (fr) Anticorps diriges contre la mesotheline utiles pour des dosages immunologiques
EP1379693A4 (fr) Codes-barres biologiques bases sur des particules a modification oligonucleotidique
EP2154245A3 (fr) Composition et procédé pour le diagnostic du cancer du rein et pour prédire le pronostic d'un patient atteint de cancer du rein
EP2993187A3 (fr) Anticorps dirigés contre her-3 et leurs utilisations
WO2006105152A3 (fr) Compositions a base de cellules amniotiques, methodes de production et utilisations desdites compositions
WO2006078289A3 (fr) Detection d'analytes cibles fondee sur des codes a barres biologiques
EP2177614A3 (fr) Composition et procédé permettant de diagnostiquer un cancer oesophagien et une métastase d'un cancer oesophagien
WO2007110678A3 (fr) Anticorps neutralisants et procédés d'utilisation
EP2241331A3 (fr) Nouveaux anticorps anti-signe DC
ATE489482T1 (de) Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
WO2007022026A3 (fr) Appareil de dosage, de synthese et de stockage, procedes de fabrication, d'utilisation et de manipulation correspondants
TW200740847A (en) Polypeptides and antibodies
EP3206031A3 (fr) Procédés, réactifs et kits pour phénotypage immunologique par cytométrie de flux
WO2005003394A3 (fr) Detection d'analytes cible a base de codes a barres biochimiques
MX2007012486A (es) Ensayos de investigacion sobre estilbazio.
WO2005036123A3 (fr) Procedes pour l'evaluation pratiquement simultanee d'un echantillon contenant une cible cellulaire et un analyte soluble
WO2005113000A3 (fr) Activité anticancéreuse d'un anticorps monoclonal anti-thymidine kinase
WO2002004956A3 (fr) Procede d'identification de peptides de liaison sensibles a la conformation et utilisations correspondantes
WO2004111636A3 (fr) Ensembles de peptides et leurs utilisations
WO2007030014A3 (fr) Recombinaison homologue dans les plantes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2550933

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004815058

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004309373

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004309373

Country of ref document: AU

Date of ref document: 20041221

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004309373

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004815058

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载